公开(公告)号：US20200283531A1

公开(公告)日：2020-09-10

申请号：US16753330

申请日：2018-10-04

申请人： NantCell, Inc.

发明人： Kayvan Niazi ,  Marcos Sixto ,  Annie Shin ,  Phil Liu

IPC分类号： C07K16/28 ,  A61K35/17 ,  C12N5/0783 ,  A61K39/39 ,  A61K9/00

摘要： Compositions, methods and uses of genetically modified NK cells to elicit immune response against cells infected with microorganisms are presented. In some embodiments, NK cells can be genetically modified with a recombinant nucleic acid that includes a segment encoding an extracellular single-chain variant fragment that specifically binds a CD1-lipid antigen complex and another segment encoding an intracellular activation domain, and a linker between those segments. In other embodiments, the NK cells can be genetically modified with a recombinant nucleic acid that includes a segment encoding an a chain T cell receptor and a β chain T cell receptor, and another segment encoding at least a portion of CD3δ and at least a portion of CD3γ. The genetically modified NK cells can be administered to the patient infected with microorganism to trigger immune response specific to the cells infected with the microorganism.